About Us

Executive Management

John Alberico — Chief Executive Officer
Kerry Skolkin — General Counsel
K. Thomas Bailey — Chief Financial Officer
David Walton — Chief Commercial Officer
Tom MacDonald — Vice President, Operations
David Olsen — Vice President, Quality Assurance, Regulatory and Clinical Affairs
Ian Harding, Ph.D. — Chief Scientific Advisor, Founder
Richard Williams, Ph.D. — Director of Scientific Development

John Alberico — Chief Executive Officer
John was the Managing Director of Inverness Medical Limited (“Inverness”) subsidiary in Scotland which manufactured the company’s glucose testing strips. During his 21-month tenure, he spearheaded efforts to increase the operation’s efficiency, building the capacity to cost-effectively produce over 1 billion test strips annually. He was also responsible for the transfer of the manufacturing of the company’s meter products to China.

Prior to Inverness, John was the Vice President of Operations for Bionostics Inc., a medical reagents and controls company, and the Vice President of Manufacturing for Nova Biomedical, a medical instrumentation company. John is also the founder of Medical Devices, Inc., an engineering consulting company specializing in the offshore contract manufacturing of high volume consumer medical devices. He holds a B.S. in Biomedical Engineering from Boston University.

Kerry Skolkin — General Counsel
Kerry is AgaMatrix’s General Counsel and Corporate Secretary, responsible for strategic management of the company’s legal affairs. Prior to joining AgaMatrix in 2009, Kerry was the chief legal officer and corporate secretary of PDI, Inc. (NASDAQ: PDII), a leading health care commercialization company providing superior insight-driven, integrated multi-channel message delivery for established and emerging health care companies. Kerry joined PDI in 2003 as Associate General Counsel and in 2006 was promoted to head the company’s legal and regulatory compliance functions. Prior to joining PDI, Kerry was an associate at Skadden, Arps, Slate, Meagher & Flom LLP in NY, specializing in corporate finance. Kerry has a J.D. with honors from the University of Chicago School of Law and bachelor’s degrees in chemistry and business administration from Carnegie-Mellon University.

K. Thomas Bailey — Chief Financial Officer
Tom Bailey joined the Company as Chief Financial Officer in March 2014. Prior to joining Agamatrix as CFO, Mr. Bailey served as President and CEO for Angiotech Pharmaceuticals Inc. until the fall of 2013, at which time he transitioned to Angiotech’s board. As CEO of Angiotech, Mr. Bailey led the company through a successful operational restructuring, and concluded the sale of one of Angiotech’s two medical device products businesses, generating significant returns for Angiotech’s shareholders. Prior to being named Angiotech’s CEO in the fall of 2011, Mr. Bailey served for six years as Angiotech’s CFO, and for two years as its Vice President, Business Development. Prior to Angiotech, Mr Bailey worked as an investment banker in the life sciences practice group at Credit Suisse First Boston and Donaldson, Lufkin & Jenrette.

Mr. Bailey currently serves as a member of the Board of Directors for Angiotech Pharmaceuticals, Inc. and LifeCare Management Services. He is a graduate of Harvard University, and also received his MBA from Harvard Business School.

David Walton — Chief Commercial Officer
Mr. Walton joined AgaMatrix in July 2014 with nearly 20 years of healthcare marketing and strategic planning experience, including his most recent role as Vice President of Marketing & Commercial Development for Echo Therapeutics, Inc., a company developing a non-invasive continuous glucose monitoring system. Dave’s executive experience also includes 11 years at Johnson & Johnson, the majority of which was spent in Johnson & Johnson’s Diabetes Care Franchise (LifeScan and Animas). There, he most recently served as Worldwide Director, Global Strategic Marketing for Insulin Delivery and Continuous Glucose Monitoring (CGM), successfully launching products such as the Animas Vibe®, an insulin pump integrated with Dexcom CGM. While at J&J, he also worked in the areas of ADHD, Parkinson’s Disease and Oncology and has received several J&J Standards of Leadership Awards. Prior to J&J, Mr. Walton spent 6 years in healthcare consulting at Deloitte Consulting and Bogart Delafield Ferrier working on various strategy and marketing engagements for health plans, hospital systems and life sciences clients. He earned his BA degree in Psychology from Princeton University and an MBA in Healthcare Management from the Wharton School at the University of Pennsylvania.

Tom MacDonald — Vice President, Operations

David Olsen — Vice President, Quality Assurance, Regulatory/Clinical Affairs
Mr. Olsen joins AgaMatrix with 25 years of experience as a Regulatory Affairs & Quality professional in the IVD, Medical Devices, Biotechnology and Biologics environment. His extensive experience in new product development and licensure within the U.S., Canada, European Union, Brazil, India and China includes his most recent role at Harvard Apparatus Regenerative Technology, Inc., a Holliston, MA biotechnology company specializing in the development of cell based tracheal prostatic where he worked as Director of Regulatory Affairs, Clinical Affairs and Quality Assurance. Among his previous roles David served as Vice President, Corporate Regulatory & Quality for 5 years at SeraCare Life Sciences, Inc., a $60M IVD Biotechnology Company specializing in the manufacture of serological and nucleic acid controls and reference materials. Dave has also held executive and management positions with Defibtech, LLC, American Red Cross, and C.R. Bard, Inc. David earned an his JD from the Massachusetts School of Law, his BS in Chemistry from Salem State University, and an LL.M. in Banking and Financial Law at Boston University School of Law.

Ian Harding, Ph.D. — Vice President, Research & Development

Richard Williams, Ph.D. — Director of Scientific Development

Richard leads the team responsible for the development of the next generation of AgaMatrix technologies and provides technical support for existing AgaMatrix products. He co-invented the patented glucose measurement algorithms at the core of AgaMatrix’s meter products. He has led the technical effort to achieve FDA 510(k) clearance of the iBGStar, the first medical device to connect directly to an iPhone and was also responsible for designing the informatics system used to monitor and troubleshoot test strip manufacturing.

Prior to joining AgaMatrix in 2004, Richard was a postdoctoral researcher at the MRC Laboratory of Molecular Biology in Cambridge, UK, where he developed novel DNA amplification technologies with applications in metagenomics, molecular ecology and molecular archaeology. Richard has a Ph.D. in Biotechnology and a B.A. (Hons) in Natural Sciences (Biochemistry) from the University of Cambridge, UK.


Board of Directors

John Alberico — Director, Chief Executive Officer
Carlos A. Ferrer — Director
Dr. Paul Kelly — Director
Jeffrey B. Kindler — Director
Vinay S. Kolla — Director
Walter Winshall — Director

John Alberico — Director, Chief Executive Officer
John was the Managing Director of Inverness Medical Limited (“Inverness”) subsidiary in Scotland which manufactured the company’s glucose testing strips. During his 21-month tenure, he spearheaded efforts to increase the operation’s efficiency, building the capacity to cost-effectively produce over 1 billion test strips annually. He was also responsible for the transfer of the manufacturing of the company’s meter products to China.

Prior to Inverness, John was the Vice President of Operations for Bionostics Inc., a medical reagents and controls company, and the Vice President of Manufacturing for Nova Biomedical, a medical instrumentation company. John is also the founder of Medical Devices, Inc., an engineering consulting company specializing in the offshore contract manufacturing of high volume consumer medical devices. He holds a B.S. in Biomedical Engineering from Boston University.

Carlos A. Ferrer — Director
Carlos A. Ferrer is a founding member of Ferrer Freeman & Company, LLC.Prior to creating FFC, Mr. Ferrer was a Managing Director at Credit Suisse First Boston. From 1982 through 1995, he developed and served as Head of CSFB’s Global Health Care Investment Banking Group. He is Vice Chairman of the Board of Trustees of the Cancer Research Institute, and a member of the Board of Directors of Ardent Health Services, LLC, GeneraMedix Pharmaceuticals Inc., OrthoRx, Inc., Preferred Care Partners Holding, Corp., and Viant Holdings, Inc. He graduated from Princeton University.

Dr. Paul Kelly — Director
Dr. Paul Kelly is Managing Director of Australian venture capital firm, OneVentures, and has held numerous executive positions in the biotechnology industry.   Paul is currently Chair of Vaxxas Pty Ltd, Hatchtech Pty Ltd and non-executive director of Charm Health Pty Ltd.

Paul co-founded NASDAQ listed Gemini Genomics plc, which was acquired by Sequenom (Nasdaq: SQNM) in 2001 and led the restructuring of another listed US company, Orchid Cellmark (Nasdaq: ORCH), generating substantial returns and exits for investors.  Dr Kelly led the seed financing of Agamatrix in 2002 and co-founded Mears Technologies Inc, a Boston based engineered materials company focused on the development and commercialization of products based on its proprietary electronic materials platform. In addition he has assisted and led a number of early-stage and mid stage companies achieve business results in order to attract funding and transform their ideas, technologies and products into sustainable successful businesses. Full Bio

Jeffrey B. Kindler — Director
Jeff Kindler is a Director at AgaMatrix and a member of President Obama’s Management Advisory Board. Kindler was formerly the Chairman and Chief Executive Officer of Pfizer, the world’s largest research-based biopharmaceutical company, which he retired from in December 2010.

Kindler earned his BA in 1977 from Tufts University summa cum laude and his JD in 1980 from Harvard magna cum laude, where he was an editor of the Harvard Law Review. He also served as a law clerk to U.S. Supreme Court Justice William J. Brennan, Jr.

In 1990, Kindler joined the General Electric Company, where he was Vice President of Litigation and Legal Policy. In 1996, he joined McDonald’s Corporation as Executive Vice President and General Counsel, responsible for both legal and corporate affairs, and then moved into line management as President of Partner Brands, which included several restaurant brands such as Boston Market and Chipotle Mexican Grill. Full Bio

Vinay S. Kolla — Director
Vinay S. Kolla is the COO/CFO of Start Media LLC, a privately held media company based in New York. Vinay is also a Managing Director of Observer Capital, an alternative investment vehicle primarily focused on real estate. Prior to founding Start Media, Vinay was a Principal at Cloverleaf Ventures and began his career in the technology, media and telecommunications group at Lazard Freres. He is a member of the Board of Directors of Start Media, Start Media/Digiplex, Wayfare Entertainment and Identitas, Inc. He is a graduate of Duke University and has an MBA from Columbia Business School.

Walter Winshall — Director
Walt is a principal in Collaborative Seed and Growth Partners, LLC, an investment firm specializing in the commercialization of early-stage technology. Previously, he was a co-founder and Chairman of SilverPlatter International, NV, a company providing information services for libraries, which was acquired by the Dutch publishing company Wolters Kluwer in 2001. He graduated from MIT in electrical engineering and from the Harvard Law School. At AgaMatrix, Walt provides guidance in corporate development strategy.